Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.

Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.

J Natl Cancer Inst. 2016 Feb 4;108(7). doi: 10.1093/jnci/djv437. Print 2016 Jul.


Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.

Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T.

Sci Rep. 2015 Jul 10;5:12122. doi: 10.1038/srep12122.


Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.

Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA.

Clin Pharmacol Ther. 2014 Aug;96(2):182-91. doi: 10.1038/clpt.2014.93. Epub 2014 Apr 29.


Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W.

Leuk Lymphoma. 2014 Jun;55(6):1304-8. doi: 10.3109/10428194.2013.833333. Epub 2013 Sep 9.


Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30.


Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.

Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA.

Cancer Chemother Pharmacol. 2012 Feb;69(2):523-31. doi: 10.1007/s00280-011-1724-7. Epub 2011 Aug 27.


Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA.

J Clin Oncol. 2011 Sep 1;29(25):3427-34. doi: 10.1200/JCO.2010.32.4962. Epub 2011 Aug 8.


Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR.

Haematologica. 2010 Jul;95(7):1098-105. doi: 10.3324/haematol.2009.017103. Epub 2010 May 11.


Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC.

J Clin Oncol. 2010 Jan 20;28(3):418-23. doi: 10.1200/JCO.2009.24.1570. Epub 2009 Dec 14.


Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC.

J Clin Oncol. 2009 Dec 10;27(35):6012-8. doi: 10.1200/JCO.2009.22.6944. Epub 2009 Oct 13.


A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.

Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL.

Cancer Chemother Pharmacol. 2010 May;66(1):151-8. doi: 10.1007/s00280-009-1145-z. Epub 2009 Sep 23.


Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT.

Blood. 2009 Mar 19;113(12):2637-45. doi: 10.1182/blood-2008-07-168583. Epub 2008 Nov 3.


Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

Xu Y, Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA.

Cancer Chemother Pharmacol. 2009 May;63(6):1073-82. doi: 10.1007/s00280-008-0826-3. Epub 2008 Sep 16.


Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.

Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA.

Ther Drug Monit. 2008 Oct;30(5):620-7. doi: 10.1097/FTD.0b013e318185813d.


Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP.

Cancer Chemother Pharmacol. 2009 Feb;63(3):517-24. doi: 10.1007/s00280-008-0769-8. Epub 2008 May 22.


Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.

Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A.

Clin Cancer Res. 2007 Feb 1;13(3):1000-9.


Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR.

Blood. 2007 Jan 15;109(2):399-404. Epub 2006 Sep 26.


Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.


Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA.

J Clin Oncol. 2006 Apr 20;24(12):1852-9.


Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.

Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML.

Am J Clin Oncol. 2006 Apr;29(2):109-15.


A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C.

Cancer Chemother Pharmacol. 2006 Aug;58(2):165-72. Epub 2005 Nov 19.


Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.

Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, Hortobagyi GN.

Clin Cancer Res. 2004 Mar 15;10(6):1943-8.


Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

Licitra EJ, Vyas V, Nelson K, Musanti R, Beers S, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH.

Clin Cancer Res. 2003 May;9(5):1673-9.


Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.

Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, Cha S, O'Fallon JR, Schaaf LJ, Miller LL.

Cancer. 2003 May 1;97(9 Suppl):2352-8.


Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.

Ann Oncol. 2001 Nov;12(11):1631-41.


Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.

Clin Cancer Res. 2000 Jun;6(6):2236-44.


Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd.

Drug Metab Dispos. 2000 Apr;28(4):423-33.


Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL.

J Clin Oncol. 1999 Sep;17(9):2710-20.


Irinotecan therapy in adults with recurrent or progressive malignant glioma.

Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL.

J Clin Oncol. 1999 May;17(5):1516-25.


Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML.

J Clin Oncol. 1999 Feb;17(2):685-96.


Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D.

J Clin Oncol. 1998 Dec;16(12):3858-65.


Alternative dosing schedules for irinotecan.

Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD.

Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Review.


Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

van Tellingen O, Nooijen WJ, Schaaf LJ, van der Valk M, van Asperen J, Henrar RE, Beijnen JH.

Cancer Res. 1998 Jun 1;58(11):2410-6.


A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH.

Cancer Chemother Pharmacol. 1998;41(5):377-84.


Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD.

J Clin Oncol. 1996 Apr;14(4):1128-35.


Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.

Shaefer MS, Rossi SJ, McGuire TR, Schaaf LJ, Collier DS, Stratta RJ.

Ann Pharmacother. 1995 Nov;29(11):1088-91.


Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

van Tellingen O, Pels EM, Henrar RE, Schaaf LJ, Padbury GE, Beijnen JH, Nooijen WJ.

J Chromatogr. 1994 Jan 14;652(1):51-8.


Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside.

Schaaf LJ, Tremel LC, Wulf BG, Vernon KK.

J Clin Pharm Ther. 1990 Oct;15(5):371-6.


Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride.

Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO.

Am J Hosp Pharm. 1990 Jul;47(7):1567-71.


Effect of an enteral nutrient formula on sustained-release theophylline absorption.

Bhargava VO, Schaaf LJ, Berlinger WG, Jungnickel PW.

Ther Drug Monit. 1989 Sep;11(5):515-9.


Effect of sucralfate on theophylline absorption in healthy volunteers.

Cantral KA, Schaaf LJ, Jungnickel PW, Monsour HP.

Clin Pharm. 1988 Jan;7(1):58-61.


The in vitro stability of doxifluridine in whole blood and plasma.

Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG.

Eur J Clin Pharmacol. 1988;34(5):533-4. No abstract available.


Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG.

Eur J Clin Pharmacol. 1987;32(4):411-8.


Influence of smoking and gender on the disposition kinetics of metoprolol.

Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, Perrier DG.

Eur J Clin Pharmacol. 1987;33(4):355-61.


Comparison of harmonic mean versus arithmetic mean clearance values.

Schaaf LJ, Lam FC, Perrier DG.

J Pharm Sci. 1986 Apr;75(4):427-9. No abstract available.


Analysis of 5'-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography.

Schaaf LJ, Ferry DG, Hung CT, Perrier DG, Edwards IR.

J Chromatogr. 1985 Aug 9;342(2):303-13.


Supplemental Content

Loading ...
Support Center